Further, several molecular profiling studies revealed that up to 48% of pancreatic cancers harbor therapeutically relevant genomic alterations, such as ERBB2, MET, FGFR1, CDK6, PIK3R3, and PIK3CA at low individual patient prevalence (3, 8, 10). Here, PIK3CA is linked to pancreatic neoplasm.